Search our Database of Scientific Publications and Authors

I’m looking for a

    8286 results match your criteria Alimentary Pharmacology and Therapeutics[Journal]

    1 OF 166

    Physicians' perspective on the clinical meaningfulness of inflammatory bowel disease trial results: an International Organization for the Study of Inflammatory Bowel Disease (IOIBD) survey.
    Aliment Pharmacol Ther 2018 Jan 19. Epub 2018 Jan 19.
    INSERM U954 and Department of Hepatogastroenterology, Nancy University Hospital, Université de Lorraine, Vandoeuvre-lès-Nancy, France.
    Background: Several novel compounds are being developed for inflammatory bowel diseases (IBD). In addition, biosimilar drugs are being approved. An increasing number of head-to-head, superiority and non-inferiority trials in patients with IBD are expected in the future. Read More

    The effectiveness and safety of ledipasvir plus sofosbuvir in adolescents with chronic hepatitis C virus genotype 4 infection: a real-world experience.
    Aliment Pharmacol Ther 2018 Jan 19. Epub 2018 Jan 19.
    Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-suef University, Beni-suef, Egypt.
    Background: The combination of ledipasvir plus sofosbuvir was recently approved for treatment of adolescent (12-17 years) HCV genotype 1, 4, 5 & 6 patients. However, few clinical trials have been performed in genotype 1 patients.

    Aim: To investigate the effectiveness and safety of ledipasvir plus sofosbuvir in chronic HCV adolescent patients with genotype 4 in the real world. Read More

    Postmarketing cases of eluxadoline-associated pancreatitis in patients with or without a gallbladder.
    Aliment Pharmacol Ther 2018 Jan 19. Epub 2018 Jan 19.
    Division of Pharmacovigilance, Office of Surveillance and Epidemiology, FDA Center for Drug Evaluation and Research, Silver Spring, MD, USA.
    Background: Cases of pancreatitis were identified in the eluxadoline clinical development program, reflected in initial product labelling, and the subject of postmarketing reports.

    Aim: To analyse postmarketing cases of eluxadoline-associated pancreatitis.

    Methods: We retrospectively analysed all US adverse event reports of pancreatitis associated with eluxadoline reported to the FDA Adverse Event Reporting System (FAERS) database from May 27, 2015 through February 15, 2017. Read More

    Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis.
    Aliment Pharmacol Ther 2018 Jan 14. Epub 2018 Jan 14.
    Johns Hopkins University, Baltimore, MD, USA.
    Background: In a 72-week, randomised controlled trial of obeticholic acid (OCA) in non-alcoholic steatohepatitis (NASH), OCA was superior to placebo in improving serum ALT levels and liver histology. OCA therapy also reduced weight.

    Aims: Because weight loss by itself can improve histology, to perform a post hoc analysis of the effects of weight loss and OCA treatment in improving clinical and metabolic features of NASH. Read More

    Clinical features and treatment of nonalcoholic fatty liver disease across the Asia Pacific region-the GO ASIA initiative.
    Aliment Pharmacol Ther 2018 Jan 14. Epub 2018 Jan 14.
    The Chinese University of Hong Kong, Hong Kong, China.
    Background: The Gut and Obesity Asia (GO ASIA) workgroup was formed to study the relationships between obesity and gastrointestinal diseases in the Asia Pacific region.

    Aim: To study factors associated with nonalcoholic steatohepatitis (NASH) and advanced fibrosis, and medical treatment of biopsy-proven nonalcoholic fatty liver disease (NAFLD) patients.

    Methods: Retrospective study of biopsy-proven NAFLD patients from centres in the GO ASIA Workgroup. Read More

    Treatment with proton pump inhibitors is associated with increased mortality in patients with pyogenic liver abscess.
    Aliment Pharmacol Ther 2018 Jan 12. Epub 2018 Jan 12.
    Department of Medicine II, Faculty of Medicine, Medical Center University of Freiburg, University of Freiburg, Freiburg, Germany.
    Background: Proton pump inhibitors (PPI) are often used in patients with gastro-esophageal reflux and peptic ulcer disease. A higher risk for infectious diseases and for pyogenic liver abscess has been reported in patients with prolonged PPI intake. Although many patients have ongoing PPI treatment after diagnosis of liver abscess, there are no data available that focus on the prognostic impact of PPI treatment in these patients. Read More

    Systematic review with meta-analysis: effectiveness and tolerability of interferon-free direct-acting antiviral regimens for chronic hepatitis C genotype 1 in routine clinical practice in Asia.
    Aliment Pharmacol Ther 2018 Jan 12. Epub 2018 Jan 12.
    Division of Gastroenterology and Hepatology, Stanford University Medical Center, Palo Alto, CA, USA.
    Background: Direct-acting antiviral (DAA) regimens have shown high efficacy and tolerability for patients with HCV genotype 1/1b (GT1/1b) in clinical trials. However, robust real-world evidence of interferon (IFN)-free DAA treatment for HCV GT1-infected patients in Asia is still lacking.

    Aim: To systematically review and meta-analyse the effectiveness and tolerability of IFN-free DAA therapy for HCV GT1 infection in Asia. Read More

    Opioid medication use in patients with gastrointestinal diagnoses vs unexplained gastrointestinal symptoms in the US Veterans Health Administration.
    Aliment Pharmacol Ther 2018 Jan 12. Epub 2018 Jan 12.
    Department of Veterans Affairs, New England Mental Illness Research, Education, and Clinical Center, West Haven, CT, USA.
    Background: While opioid prescriptions have increased alarmingly in the United States (US), their use for unexplained chronic gastrointestinal (GI) pain (eg, irritable bowel syndrome) carries an especially high risk for adverse effects and questionable benefit.

    Aim: To compare opioid use among US veterans with structural GI diagnoses (SGID) and those with unexplained GI symptoms or functional GI diagnoses (FGID), a group for whom opioids have no accepted role.

    Methods: Veterans Health Administration (VHA) administrative data from fiscal year 2012 were used to identify veterans with diagnostic codes recorded for SGID and FGID. Read More

    Non-invasive evaluation of portal hypertension using shear-wave elastography: analysis of two algorithms combining liver and spleen stiffness in 191 patients with cirrhosis.
    Aliment Pharmacol Ther 2018 Jan 11. Epub 2018 Jan 11.
    Service d'Hépatologie, Hôpital Beaujon, Assistance Publique Hôpitaux de Paris, Clichy, France.
    Background: Two algorithms based on sequential measurements of liver and spleen stiffness using two-dimensional shearwave elastography (2D-SWE) have been recently proposed to estimate clinically significant portal hypertension (hepatic venous pressure gradient [HVPG] ≥10 mm Hg) in patients with cirrhosis, with excellent diagnostic accuracy.

    Aim: To validate externally these algorithms in a large cohort of patients with cirrhosis.

    Methods: One hundred and ninety-one patients with stable cirrhosis (Child-Pugh class A 39%, B 29% and C 31%) who underwent liver and spleen stiffness measurements using 2D-SWE at the time of HVPG measurement were included. Read More

    Role of bisphenol A as environmental factor in the promotion of non-alcoholic fatty liver disease: in vitro and clinical study.
    Aliment Pharmacol Ther 2018 Jan 11. Epub 2018 Jan 11.
    Department of Clinical and Experimental Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
    Background: Bisphenol A is an endocrine disrupting chemical associated with type 2 diabetes mellitus (T2DM), cardiovascular disease and liver enzyme abnormalities.

    Aim: To evaluate bisphenol A plasma and urine levels in non-alcoholic fatty liver disease (NAFLD) patients compared to healthy subjects. Furthermore, we evaluated, in human HepG2 cells, the effects of exposure to different concentrations of bisphenol A on both oxidative stress induction and cell proliferation. Read More

    Review article: coeliac disease in later life must not be missed.
    Aliment Pharmacol Ther 2018 Jan 11. Epub 2018 Jan 11.
    Department of Medicine, Faculty of Medicine and Life-Sciences, Tampere University Hospital, University of Tampere, Tampere, Finland.
    Background: The presenting symptoms of coeliac disease are often subtle and the diagnosis is frequently delayed or overlooked. Therefore, especially elderly patients may be denied the benefits conferred by gluten free diet which can be dramatically life-changing.

    Aim: To review the occurrence, clinical features, diagnosis and management in coeliac patients detected later in life. Read More

    Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.
    Aliment Pharmacol Ther 2018 Jan 8. Epub 2018 Jan 8.
    Lille, France.
    Background: Long-term outcome of ustekinumab in Crohn's disease (CD) has not been evaluated.

    Aim: To evaluate the long-term efficacy and safety of ustekinumab and identify the predictive factors of ustekinumab failure-free persistence in a cohort of anti-TNF refractory CD patients.

    Methods: We performed a retrospective multicentre cohort study including all consecutive CD patients who began subcutaneous ustekinumab and presented a clinical response (defined as a significant improvement of CD-related clinical symptoms assessed by the patient's physician leading to continued ustekinumab) during the first year of treatment. Read More

    Sofosbuvir plus daclatasvir with or without ribavirin in 551 patients with hepatitis C-related cirrhosis, genotype 4.
    Aliment Pharmacol Ther 2018 Jan 3. Epub 2018 Jan 3.
    Rheumatology Department, Cairo University, Cairo, Egypt.
    Background: The Daclatasvir and Sofosbuvir combination therapy (SOF/DCV) has shown efficacy in patients with chronic hepatitis C in clinical trials.

    Aim: To investigate the efficacy and safety of SOF/DCV for treatment of patients with hepatitis C-related liver cirrhosis genotype 4.

    Methods: Multicentre study involving 551 patients with liver cirrhosis genotype 4; 432 naïve patients and 119 treatment-experienced patients. Read More

    Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated.
    Aliment Pharmacol Ther 2018 Feb;47(3):441-442
    Department of Medicine Huddinge, Karolinska Institutet Center for Digestive Disease, Division of Hepatology, Karolinska University Hospital, Stockholm, Sweden.

    Hospice care in Medicare patients with primary liver cancer: the impact on resource utilisation and mortality.
    Aliment Pharmacol Ther 2018 Jan 3. Epub 2018 Jan 3.
    Department of Medicine, Center For Liver Disease, Inova Fairfax Hospital, Falls Church, VA, USA.
    Background: Few studies have assessed the impact of hospice care in patients with primary liver cancer.

    Aim: To examine the determinants of hospice care and its effects on resource utilisation and survival among Medicare beneficiaries with primary liver cancer.

    Methods: We utilised the Surveillance, Epidemiology and End result Registry (SEER) database from 2002 to 2009 for this cross-sectional study. Read More

    Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease.
    Aliment Pharmacol Ther 2017 Dec 22. Epub 2017 Dec 22.
    Birmingham, UK.
    Background: Validated diagnostic tools that are accurate, cost effective and acceptable to patients are required for disease stratification and monitoring in NAFLD.

    Aims: To investigate the performance and cost of multiparametric MRI alongside existing biomarkers in the assessment of NAFLD.

    Methods: Adult patients undergoing standard of care liver biopsy for NAFLD were prospectively recruited at two UK liver centres and underwent multiparametric MRI, blood sampling and transient elastography withing 2 weeks of liver biopsy. Read More

    Viral kinetics analysis and virological characterization of treatment failures in patients with chronic hepatitis C treated with sofosbuvir and an NS5A inhibitor.
    Aliment Pharmacol Ther 2017 Dec 22. Epub 2017 Dec 22.
    Department of Virology, Henri Mondor Hospital, National Reference Center for Viral Hepatitis B, C and D, University of Paris-Est, Créteil, France.
    Background: The combination of sofosbuvir (SOF) plus an NS5A inhibitor for 12 weeks is highly efficacious in patients with chronic hepatitis C. As the costs of generic production of sofosbuvir and NS5A inhibitor are rapidly decreasing, the combination of these DAAs will be the standard treatment in most low- to middle-income countries in the future.

    Aim: To identify key predictors of response that can be used to tailor treatment decisions. Read More

    HLA-DQA1-HLA-DRB1 polymorphism is a major predictor of azathioprine-induced pancreatitis in patients with inflammatory bowel disease.
    Aliment Pharmacol Ther 2017 Dec 22. Epub 2017 Dec 22.
    Division of Clinical Pharmacology, Department of Medicine, Western University, London, ON, Canada.
    Background: Azathioprine (AZA)-induced pancreatitis is an unpredictable and dose-independent adverse event affecting 2%-7% of patients with inflammatory bowel disease (IBD) patients treated with AZA. There are no tools in clinical practice to identify at-risk individuals; however, a genome wide association study (GWAS) identified a strong association between the Class II HLA gene region polymorphism (rs2647087) and thiopurine-induced pancreatitis.

    Aim: To independently confirm the findings of the GWAS in an IBD cohort, to evaluate its utility in clinical practice and to offer a novel AZA treatment algorithm for IBD based on pharmacogenomic principles. Read More

    Vedolizumab in the treatment of chronic, antibiotic-dependent or refractory pouchitis.
    Aliment Pharmacol Ther 2017 Dec 19. Epub 2017 Dec 19.
    Practice of Internal Medicine, Oldenburg, Germany.
    Background: The most common complication after ileal pouch anal anastomosis in up to 50% of patients is an acute pouchitis. The majority of patients respond to antibiotic treatment. However, 10%-15% develops chronic antibiotic-dependent or refractory pouchitis which is usually hard to treat. Read More

    Soluble CD163 and soluble mannose receptor predict survival and decompensation in patients with liver cirrhosis, and correlate with gut permeability and bacterial translocation.
    Aliment Pharmacol Ther 2017 Dec 21. Epub 2017 Dec 21.
    Department of Gastroenterology and Hepatology, Medical University of Graz, Austria.
    Background: Activated hepatic macrophages play a key role in inflammation and fibrosis progression in chronic liver disease.

    Aim: To assess the prognostic value of soluble (s)CD163 and mannose receptor (sMR) in cirrhotic patients and explore associations with markers of intestinal permeability (lactulose-mannitol ratio, diamine oxidase), bacterial translocation (endotoxin, lipopolysaccharide-binding protein) and markers of systemic immune activation (interleukin-6, interleukin-8, sCD14).

    Methods: We prospectively investigated 101 cirrhotic patients (Child-Pugh class A: n = 72, Child-Pugh classes B and C: n = 29) and 31 healthy controls. Read More

    1 OF 166